Navigation Links
Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer
Date:9/26/2011

OSLO, Norway, September 27, 2011 /PRNewswire/ --

 

  • Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US
  • Photocure to commercialise the product directly in the US market

Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the execution of a new commercial strategy for Hexvix, its flagship product  to aid in diagnosing bladder cancer.  Photocure has entered into a strategic collaboration with Ipsen, a global specialty-driven biopharmaceutical company focused on four franchises, including uro-oncology, to commercialise Hexvix worldwide, excluding the US and Nordic region. Additionally, to capitalise on the untapped US market opportunity, Photocure plans to launch the product, approved as Cysview™ in the US, through its own commercial operations.  The new strategy will maximise the potential of Hexvix on a global basis.

Hexvix has been the first significant advance for the improved detection of bladder cancer.  It is designed to induce specific fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect bladder cancer. Hexvix, initially approved in Sweden in 2004, was approved across Europe by 2006 and as Cysview in the US in 2010. Since 2006, the product has been commercialized in Europe by GE Healthcare. Hexvix was initially approved in the EU based on strong clinical data showing improved detection of bladder cancer[1]. More recently, new clinical data has shown that improved detection using Hexvix makes local surgery more complete and leads to significant reduction in the recurrence of bladder cancer[2]. Based on this, Hexvix has the potential to transform the diagnosis of bladder cancer and may significantly
'/>"/>

SOURCE Photocure ASA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014  AxelaCare Health Solutions, ... services, announced today that it has acquired Advanced Care, ... intravenous therapy provider.  Terms of the transaction were not ... AxelaCare,s intravenous solutions pharmacies to 18 nationwide and expands ... New York - New Jersey ...
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014  Columbia ... that its subsidiary, Molecular Profiles Ltd., is set to ... annual CPhI/ICSE Worldwide event in Paris ... the rapid development of both standard and complex drug ... which incorporates the company,s existing formulation and analytical development ...
Breaking Medicine Technology:AxelaCare Health Solutions Acquires Advanced Care of New York 2AxelaCare Health Solutions Acquires Advanced Care of New York 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3
... Presented at the World Muscle Society International ... PTC Therapeutics, Inc.,(PTC), a biopharmaceutical company ... small-molecule drugs targeting,post-transcriptional control mechanisms, today announced ... of PTC124 in patients with Duchenne muscular,dystrophy ...
... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... clinical and preclinical data on its lead ... the American Association for,Cancer Research (AACR), National ... and Treatment of Cancer (EORTC) entitled,"International Conference ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... your risk for high blood pressure, a new study suggests. ... within 109 yards of a busy road had a 22 ... living at least half a mile away, researchers report. ... our physical environment on our health and well-being," said lead ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
(Date:10/1/2014)... modelling of the human eye, the brain of a ... and new technology, says a QUT leading robotics researcher. ... Engineering Faculty says the new study uses new computer ... high-density buildings or tunnels. , "This is a very ... putting two halves of a thing together because we,re ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Reno, Nev. (PRWEB) October 01, 2014 ... through measuring abnormal circadian cellular changes throughout the body, ... Health, Inc. to better address the company’s breadth of ... wearable early breast cancer screening technology. , “Our initial ... breast cancer system which detects abnormal circadian cellular changes ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Medical discovery first step on path to new painkillers 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... in our nation, Americans are very optimistic about the ... recent nationwide survey sponsored by Abbott, nearly two-thirds (64%) ... cancer. ,"As an organization researching new options ... efforts will live up to the optimism expressed by ...
... Suffering from acute or chronic lower back pain? There ... Medicine Center locally in Fairview, N.J, which will ... are only a handful of these machines in Bergen ... center, who administers non-invasive Intervertebral Disc Decompression (IDD) therapy. ...
... A teenage girl has died of bird flu in Indonesia, taking ... to 79, a health ministry official said Friday. ... to hospital on the main island of Java, the official said. ... chicken at her home in Kendal district in Central Java, said ...
... politician Abdel Aziz al-Hakim returned to Iraq's holy city of ... ,Hakim, the head of one of the most ... in a trip that included medical tests in the United ... his headquarters in Najaf and will be there for a ...
... earlier believed, a new study carried out by the ... ,According to the satellite-based research undertaken by Frank ... precipitation has also kept pace. ,The findings ... to accurately predict precipitation on regional scales. ...
... Scientists at the Chinese University in Hong Kong have identified ... may hold clues to male infertility . ,As part ... defective versions of the protein. They found that the sperms ... those of normal mice. ,'(The protein) is involved ...
Cached Medicine News:Health News:Americans Optimistic About the War on Cancer 2Health News:Indonesian Teenager Dies of Bird Flu 2Health News:Top Iraqi Shiite Leader Returns Home 2Health News:World may Get Much Wetter With Global Warming Than Believed 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: